Nico van Zandwijk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6417930/publications.pdf

Version: 2024-02-01

250 papers	16,641 citations	13854 67 h-index	17090 122 g-index
322 all docs	322 docs citations	322 times ranked	15528 citing authors

#	Article	IF	Citations
1	Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer. New England Journal of Medicine, 1992, 326, 524-530.	13.9	1,222
2	K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung. New England Journal of Medicine, 1990, 323, 561-565.	13.9	769
3	Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 442-450.	3.0	647
4	Mutational Activation of the K-rasOncogene. New England Journal of Medicine, 1987, 317, 929-935.	13.9	518
5	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncology, The, 2017, 18, 1386-1396.	5.1	508
6	Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PLoS ONE, 2011, 6, e24145.	1.1	442
7	Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology, 2011, 80, 193-208.	2.0	421
8	Randomized phase II trial of gemcitabineâ€“cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Annals of Oncology, 2004, 15, 19-27.	0.6	351
9	EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer. Journal of the National Cancer Institute, 2000, 92, 977-986.	3.0	322
10	High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy. Clinical Cancer Research, 2010, 16, 5805-5813.	3.2	279
11	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 2013, 4, 94.	1.1	266
12	Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer, 2005, 47, 69-80.	0.9	263
13	Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology, 1998, 16, 2133-2141.	0.8	260
14	Photodynamic therapy: a promising new modality for the treatment of cancer. Journal of Photochemistry and Photobiology B: Biology, 1996, 34, 3-12.	1.7	253
15	Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8362-8370.	0.8	243
16	Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nature Genetics, 2002, 31, 295-300.	9.4	239
17	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 2013, 24, 3128-3135.	0.6	221
18	Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology, 1996, 14, 814-820.	0.8	204

#	Article	IF	Citations
19	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. Journal of Thoracic Oncology, 2017, 12, 194-207.	0.5	186
20	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 2016, 8, 1079-1085.	1.0	176
21	Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 2013, 5, E254-307.	0.6	170
22	Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.. Journal of Clinical Oncology, 1997, 15, 317-329.	0.8	167
23	Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). European Journal of Cancer, 2007, 43, 114-121.	1.3	166
24	Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2038-2045.	0.8	149
25	Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Nonâ€“Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). Journal of Clinical Oncology, 2000, 18, 2658-2664.	0.8	146
26	Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. European Journal of Cancer & Clinical Oncology, 1987, 23, 1409-1411.	0.9	142
27	Relationship Between Cisplatin Administration and the Development of Ototoxicity. Journal of Clinical Oncology, 2006, 24, 918-924.	0.8	141
28	Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology, 2004, 15, 419-426.	0.6	140
29	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Annals of Oncology, 2007, 18, 99-103.	0.6	136
30	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Nonâ€“Small-Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 284-290.	3.2	134
31	Physical and psychosocial consequences of total laryngectomy. Clinical Otolaryngology, 1990, 15, 421-425.	0.6	130
32	Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer, 2005, 50, 83-86.	0.9	128
33	Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer, 1991, 67, 2033-2037.	2.0	127
34	Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occupational and Environmental Medicine, 2017, 74, 851-858.	1.3	122
35	Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. Journal of Thoracic Oncology, 2010, 5, 1616-1622.	0.5	121
36	The MARS feasibility trial: conclusions not supported by data. Lancet Oncology, The, 2011, 12, 1093-1094.	5.1	121

#	Article	IF	Citations
37	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant PleuralÂMesothelioma. Journal of Thoracic Oncology, 2017, 12, 1421-1433.	0.5	121
38	In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiotherapy and Oncology, 2004, 72, 333-339.	0.3	117
39	A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology, 2012, 23, 72-77.	0.6	116
40	Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1184-1191.	0.5	115
41	The influence of a heat and moisture exchanger (HME) on the respiratory symptoms after total laryngectomy. Clinical Otolaryngology, 1991, 16, 152-156.	0.6	114
42	Identification of recurrent <scp>FGFR3</scp> fusion genes in lung cancer through kinomeâ€centred <scp>RNA</scp> sequencing. Journal of Pathology, 2013, 230, 270-276.	2.1	113
43	Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target. PLoS ONE, 2008, 3, e0001722.	1.1	105
44	Value of resection of pulmonary metastases in head and neck cancer patients. , 1996, 18, 311-316.		104
45	Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. British Journal of Cancer, 1997, 76, 819-826.	2.9	104
46	Cytoreductive Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy in Patients With Malignant Pleural Mesothelioma or Pleural Metastases of Thymoma. Chest, 2002, 121, 480-487.	0.4	104
47	Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Journal of Clinical Pathology, 2013, 66, 847-853.	1.0	104
48	Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury. Radiotherapy and Oncology, 1995, 36, 15-23.	0.3	103
49	N-Acetylcysteine (NAC) and glutathione (GSH): Antioxidant and chemopreventive properties, with special reference to lung cancer. Journal of Cellular Biochemistry, 1995, 59, 24-32.	1.2	102
50	Polycyclic aromatic hydrocarbonâ€"DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. Carcinogenesis, 1992, 13, 987-993.	1.3	98
51	Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer, 2005, 48, 291-296.	0.9	98
52	Morbidity and mortality in the surgery arm of EORTC 08941 trial. European Respiratory Journal, 2005, 26, 192-197.	3.1	93
53	Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.. Journal of Clinical Oncology, 1997, 15, 285-291.	0.8	88
54	Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. Carcinogenesis, 1990, 11, 1677-1681.	1.3	87

#	Article	IF	Citations
55	Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?. Clinical Cancer Research, 2005, 11, 6608-6614.	3.2	87
56	Prognostic Significance of 99mTc Hynic-rh-Annexin V Scintigraphy During Platinum-Based Chemotherapy in Advanced Lung Cancer. Journal of Clinical Oncology, 2007, 25, 2534-2539.	0.8	86
57	Improvements in Respiratory and Psychosocial Functioning following Total Laryngectomy by the Use of a Heat and Moisture Exchanger. Annals of Otology, Rhinology and Laryngology, 1993, 102, 878-883.	0.6	85
58	Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis, 1998, 19, 819-825.	1.3	83
59	Intraoperative Photodynamic Therapy After Pleuropneumonectomy in Patients With Malignant Pleural Mesothelioma. Chest, 2001, 120, 1167-1174.	0.4	83
60	The value of [18F]fluoro-2-deoxy-?-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer, 2003, 39, 151-157.	0.9	83
61	Dose-effect relations for local functional and structural changes of the lung after irradiation for malignant lymphoma. Radiotherapy and Oncology, 1994, 32, 201-209.	0.3	82
62	Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 2011, 6, 1923-1929.	0.5	82
63	Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. European Journal of Cancer & Clinical Oncology, 1991, 27, 431-435.	0.9	80
64	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. British Journal of Cancer, 1996, 74, 961-963.	2.9	78
65	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 2015, 6, 23480-23495.	0.8	76
66	Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. European Journal of Cancer, 1993, 29, 1720-1722.	1.3	75
67	High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 551-553.	0.4	71
68	A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data. Radiotherapy and Oncology, 1993, 29, 110-116.	0.3	71
69	The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Annals of Thoracic Surgery, 2003, 75, 1715-1718.	0.7	69
70	Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. British Journal of Cancer, 2014, 111, 1860-1869.	2.9	68
71	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 2015, 113, 963-969.	2.9	68
72	MiRâ€Score: A novel 6â€microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 2015, 9, 715-726.	2.1	67

#	Article	IF	Citations
73	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1467-1469.	2.5	66
74	The EUROSCAN Study. British Journal of Cancer, 1991, 64, 985-989.	2.9	65
75	Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology, 1995, 13, 660-665.	0.8	62
76	The activity of raltitrexed (TomudexÂ®) in malignant pleural mesothelioma. European Journal of Cancer, 2003, 39, 353-357.	1.3	62
77	Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology, 1992, 10, 824-828.	0.8	61
78	Amiodarone pneumonitis: three further cases with a review of published reports.. Thorax, 1984, 39, 57-64.	2.7	60
79	Cell-free microRNAs: potential biomarkers in need of standardized reporting. Frontiers in Genetics, 2013, 4, 56.	1.1	60
80	Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical Pathology, 2013, 66, 854-861.	1.0	54
81	Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 602-605.	0.5	53
82	Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Annals of Oncology, 2004, 15, 786-792.	0.6	51
83	The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Critical Reviews in Oncology/Hematology, 2012, 84, 200-212.	2.0	51
84	Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC lung cancer cooperative group. European Journal of Cancer & Clinical Oncology, 1991, 27, 1627-1629.	0.9	50
85	Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 2013, 14, 70-77.	1.1	50
86	The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Frontiers in Oncology, 2019, 9, 1366.	1.3	50
87	Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC lung cancer cooperative group. European Journal of Cancer, 1997, 33, 2211-2215.	1.3	49
88	NCAM and lung cancer. International Journal of Cancer, 1994, 57, 34-37.	2.3	48
89	Heat and moisture exchangers as a treatment option in the post-operative rehabilitation of laryngectomized patients. Clinical Otolaryngology, 1995, 20, 504-509.	0.6	47
90	Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase iii study of the eortc lung cancer cooperative group. European Journal of Cancer, 1997, 33, 1759-1766.	1.3	47

#	Article	IF	Citations
91	Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 2237-2244.	3.2	47
92	The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review. European Archives of Oto-Rhino-Laryngology, 2006, 263, 1-8.	0.8	46
93	KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 2016, 15, 44.	7.9	46
94	Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomarker Research, 2021, 9, 11.	2.8	46
95	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 2014, 110, 510-519.	2.9	45
96	Recovery of overall and local lung function loss 18 months after irradiation for malignant lymphoma.. Journal of Clinical Oncology, 1996, 14, 1431-1441.	0.8	41
97	A pilot study of photodynamic therapy in patients with inoperable non-small cell lung cancer. European Journal of Cancer, 1992, 28, 1370-1373.	1.3	40
98	Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982â€“2009. Occupational and Environmental Medicine, 2016, 73, 187-194.	1.3	40
99	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 258-272.	0.5	40
100	PILOT STUDY ON LIGHT DOSIMETRY FOR ENDOBRONCHIAL PHOTODYNAMIC THERAPY. Photochemistry and Photobiology, 1993, 58, 92-99.	1.3	38
101	Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. European Journal of Cardio-thoracic Surgery, 2009, 36, 741-746.	0.6	38
102	Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 2013, 21, 697-705.	1.0	38
103	Effect of N-acetylcysteÃ¯ne on photofrin-induced skin photosensitivity in patients. Lasers in Surgery and Medicine, 1995, 16, 359-367.	1.1	37
104	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Journal of Thoracic Disease, 2018, 10, 3909-3921.	0.6	35
105	Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. British Journal of Cancer, 2003, 89, S9-S14.	2.9	33
106	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2013, 8, e70940.	1.1	33
107	Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: A dose finding study. International Journal of Radiation Oncology Biology Physics, 1986, 12, 379-383.	0.4	32
108	Neoadjuvant (Induction) Erlotinib Response in Stage IIIA Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 4205-4207.	0.8	32

#	Article	IF	Citations
109	Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. Lung Cancer, 2011, 74, 274-279.	0.9	32
110	MesomiR 1: A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC). Annals of Oncology, 2015, 26, ii16.	0.6	32
111	FGF2 and EGF induce epithelialâ€“mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis, 2018, 39, 534-545.	1.3	32
112	Malignant mesothelioma. Internal Medicine Journal, 2010, 40, 742-750.	0.5	31
113	ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2013, 8, 1317-1328.	0.5	30
114	Prognostic factors in NSCLC. Recent experiences. Lung Cancer, 1995, 12, S27-S33.	0.9	29
115	The prognostic significance of a previous malignancy in operable non-small cell lung cancer. Lung Cancer, 2001, 32, 47-53.	0.9	29
116	Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer, 2001, 34, S145-S150.	0.9	29
117	Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. Journal of Clinical Oncology, 1996, 14, 127-134.	0.8	27
118	Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 893-899.	3.3	27
119	Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients. Lung Cancer, 2008, 59, 385-390.	0.9	27
120	Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2016, 19, 173-189.	2.9	27
121	A link between the fibroblast growth factor axis and the miRâ€16 family reveals potential new treatment combinations in mesothelioma. Molecular Oncology, 2018, 12, 58-73.	2.1	27
122	Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future. Frontiers in Oncology, 2020, 10, 105.	1.3	27
123	Pulmonary morbidity 10â€“18 years after irradiation for Hodgkin's disease. European Journal of Cancer, 1993, 29, 343-347.	1.3	26
124	N-Acetylcysteine for Lung Cancer Prevention. Chest, 1995, 107, 1437-1441.	0.4	26
125	Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 2011, 43, 128-132.	0.3	26
126	Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins Î±vÎ²3 and Î±vÎ²5. PLoS ONE, 2014, 9, e90374.	1.1	26

#	Article	IF	Citations
127	Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. European Journal of Cancer & Clinical Oncology, 1990, 26, 738-740.	0.9	25
128	Asbestos-related cancers: the â€˜Hidden Killerâ€™ remains a global threat. Expert Review of Anticancer Therapy, 2020, 20, 271-278.	1.1	25
129	Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided. Lung Cancer, 2010, 68, 222-227.	0.9	24
130	Inflammation in malignant mesothelioma - friend or foe?. Annals of Cardiothoracic Surgery, 2012, 1, 516-22.	0.6	24
131	Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. British Journal of Cancer, 2006, 94, 1375-1382.	2.9	23
132	CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer, 2008, 60, 57-61.	0.9	22
133	Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head and Neck, 2009, 31, 220-226.	0.9	22
134	Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model. International Journal of Cancer, 1994, 56, 880-885.	2.3	21
135	Treatment of metastatic non-small cell lung cancer. Current Opinion in Oncology, 1996, 8, 120-125.	1.1	21
136	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma â€“ A multi-institutional study. European Journal of Cancer, 2016, 63, 64-73.	1.3	21
137	Prevalence of neuroendocrine granules in small cell lung carcinoma. Usefulness of electron microscopy in lung cancer classification. Journal of Pathology, 1986, 149, 41-47.	2.1	20
138	The need for immediate monitoring of treatment parameters and uniform assessment of patient data in clinical trials. European Journal of Cancer & Clinical Oncology, 1991, 27, 615-619.	0.9	20
139	Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 367-368.	0.9	20
140	Teniposide sometimes effective in brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology, 1999, 41, 285-289.	1.4	20
141	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 2016, 114, 524-531.	2.9	20
142	The â€˜grey areaâ€™ between small cell and non-small cell lung carcinomas. Light and electron microscopy versus clinical data in 14 cases. Journal of Pathology, 1986, 149, 49-54.	2.1	19
143	Second primary cancers in the lung in head and neck cancer patients: a Challenge. European Journal of Cancer & Clinical Oncology, 1987, 23, 883-886.	0.9	19
144	Chemoprevention in the management of oral cancer: EUROSCAN and other studies. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 153-157.	0.9	19

#	Article	IF	Citations
145	PARTIAL PROTECTION OF PHOTODYNAMIC-INDUCED SKIN REACTIONS IN MICE BY N-ACETYLCYSTEINE: A PRECLINICAL STUDY. Photochemistry and Photobiology, 1994, 59, 448-454.	1.3	19
146	Chemoprevention of lung cancer: current status and future prospects. Lung Cancer, 2003, 42, 71-79.	0.9	19
147	The Influence of Fluticasone Inhalation on Markers of Carcinogenesis in Bronchial Epithelium. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1061-1065.	2.5	19
148	Improvements in the Assessment of Pulmonary Function in Laryngectomized Patients. Laryngoscope, 1993, 103, 1391???1394.	1.1	18
149	Differential Diagnosis of Pulmonary Carcinoma Following Head and Neck Cancer by Genetic Analysis. Clinical Cancer Research, 2009, 15, 980-985.	3.2	18
150	Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972â€“2009. Australian and New Zealand Journal of Public Health, 2016, 40, 255-262.	0.8	18
151	Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma. European Journal of Cancer & Clinical Oncology, 1990, 26, 373-376.	0.9	17
152	High Dose Rate Brachytherapy Improves Resectability in Squamous Cell Lung Cancer. Chest, 1992, 102, 308-309.	0.4	17
153	The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. European Journal of Cancer, 1996, 32, 1490-1497.	1.3	17
154	Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology, 2011, 43, 313-317.	0.3	17
155	Molecular biomarkers in malignant mesothelioma: state of the art. Pathology, 2011, 43, 201-212.	0.3	16
156	Patterns of care for malignant pleural mesothelioma patients compensated by the <scp>D</scp>ust <scp>D</scp>iseases <scp>B</scp>oard in <scp>N</scp>ew <scp>S</scp>outh <scp>W</scp>ales, <scp>A</scp>ustralia. Internal Medicine Journal, 2013, 43, 402-410.	0.5	16
157	Hitting the Bullâ€™s-Eye: Mesothelinâ€™s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. Cancers, 2021, 13, 3932.	1.7	16
158	Smokers and urinary genotoxins: Implications for selection of cohorts and modulation of endpoints in chemoprevention trials. Journal of Cellular Biochemistry, 1996, 63, 92-98.	1.2	15
159	New methods for early diagnosis of lung cancer. Lung Cancer, 2002, 38, S9-S11.	0.9	15
160	Chemoprevention in lung carcinogenesis â€“ An overview. European Journal of Cancer, 2005, 41, 1990-2002.	1.3	15
161	Immunotherapy in Nonâ€“Small-Cell Lung Carcinoma: From Inflammation to Vaccination. Clinical Lung Cancer, 2009, 10, 99-105.	1.1	15
162	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy. Cancer Research, 2015, 75, 3976-3976.	0.4	15

#	Article	IF	Citations
163	Epirubicin in previously untreated patients with small cell lung cancer: A phase II study by the EORTC lung cancer cooperative group. European Journal of Cancer, 1992, 28, 1667-1670.	1.3	14
164	Influence of heat and moisture exchanger respiratory load on transcutaneous oxygenation in laryngectomized individuals: A randomized crossover study. Head and Neck, 2007, 29, 1102-1110.	0.9	14
165	N-isopropyl-p[123I]iodoamphetamine, a new agent for lung imaging studies.. Thorax, 1986, 41, 801-803.	2.7	13
166	The radioprotective effect of N-acetylcysteine in thorax irradiation of mice. Radiotherapy and Oncology, 1987, 10, 67-69.	0.3	13
167	Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. British Journal of Cancer, 2003, 88, 814-821.	2.9	13
168	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget, 2019, 10, 4125-4138.	0.8	13
169	Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer, 2003, 42, 3-6.	0.9	12
170	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 587-599.	0.7	12
171	Update in lung cancer: Prologue to a modern review series. Respirology, 2015, 20, 183-184.	1.3	12
172	Lung volume calculations from 81 Kr m SPECT for the quantification of regional ventilation. Clinical Physics and Physiological Measurement: an Official Journal of the Hospital Physicists' Association, Deutsche Gesellschaft Fur Medizinische Physik and the European Federation of Organisations for Medical Physics, 1988, 9, 147-154.	0.5	11
173	Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. British Journal of Cancer, 1996, 73, 439-446.	2.9	11
174	Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. Theranostics, 2021, 11, 7092-7109.	4.6	11
175	Interaction of the bioreductive drug sr 4233 and photodynamic therapy using photofrin in a mouse tumor model. International Journal of Radiation Oncology Biology Physics, 1993, 27, 665-670.	0.4	10
176	The EUROSCAN study: A progress report. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 1993, 14, 62-66.	0.6	10
177	Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. European Journal of Cancer, 2006, 42, 1391-1398.	1.3	10
178	Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: A randomized phase II trial of the EORTC lung cancer cooperative group. Annals of Oncology, 1996, 7, 637-639.	0.6	9
179	Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 273-279.	0.7	9
180	Management of Progressive Pulmonary Nodules FoundÂduring and outside of CT Lung Cancer Screening Studies. Journal of Thoracic Oncology, 2017, 12, 1755-1765.	0.5	9

#	Article	IF	Citations
181	The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. BMC Research Notes, 2017, 10, 600.	0.6	9
182	A randomised phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER2-positive non-small cell lung cancer (nsclc). European Journal of Cancer, 2001, 37, S50.	1.3	8
183	StratÃ©gie thÃ©rapeutique de chimiothÃ©rapie nÃ©oadjuvante du cancer bronchique non Ã petites cellules: intÃ©rÃªt de la gemcitabine. Anti-Cancer Drugs, 2001, 12, S15-S19.	0.7	8
184	The psychological impact of annual chest X-ray follow-up in head and neck cancer. Acta Oto-Laryngologica, 2006, 126, 1315-1320.	0.3	8
185	Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer, 2013, 21, 1879-1884.	1.0	8
186	Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer, 2013, 14, 164-171.	1.1	8
187	Awareness: potential toxicities of carbon nanotubes. Translational Lung Cancer Research, 2019, 8, S471-S472.	1.3	8
188	Chemoprevention strategies for non-small cell lung cancer. Current Opinion in Oncology, 2002, 14, 185-190.	1.1	7
189	Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs, 2005, 16, 1029-1036.	0.7	7
190	Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. Respirology, 2017, 22, 978-985.	1.3	7
191	Response to â€œAn innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)â€• Translational Lung Cancer Research, 2018, 7, S60-S61.	1.3	7
192	Tracheal obstruction after placement of a metal wire expandable stent (Wallstent). Lung Cancer, 1995, 12, 77-80.	0.9	6
193	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	2.0	6
194	New treatment opportunities in non-small cell lung cancer. Lung Cancer, 1993, 9, 109-116.	0.9	5
195	Radioimmunotherapy of small-cell lung cancer xenografts using131I-labelled anti-NCAM monoclonal antibody 123C3. Cancer Immunology, Immunotherapy, 1995, 41, 169-174.	2.0	5
196	Randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients with cancer of the upper and lower airways: the EUROSCAN study. European Journal of Cancer, 1999, 35, S82.	1.3	5
197	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 2016, 9, 44-49.	1.3	5
198	Update in lung cancer: epilogue to a modern review series. Respirology, 2016, 21, 789-790.	1.3	5

#	Article	IF	Citations
199	Potential toxicities of carbon nanotubes: time for a reminder. Expert Review of Respiratory Medicine, 2020, 14, 339-340.	1.0	5
200	Asbestos and Zeolites: from A to Z via a Common Ion. Chemical Research in Toxicology, 2021, 34, 936-951.	1.7	5
201	Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. , 2019, 2, 1193-1206.		5
202	Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 85-92.	0.7	4
203	Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. FASEB BioAdvances, 2019, 1, 550-560.	1.3	4
204	Clinical practice guidelines for malignant pleural mesothelioma. Journal of Thoracic Disease, 2013, 5, 724-5.	0.6	4
205	Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clinical Cancer Research, 2003, 9, 3526-33.	3.2	4
206	Pulmonary Injury Elicited by Blood: An Experimental Study. European Surgical Research, 1979, 11, 301-316.	0.6	3
207	Photodynamic Therapy as an Alternative Treatment for Surgery in a Patient with Lung Cancer Undergoing Bone Marrow Transplantation. Chest, 1993, 103, 1908-1909.	0.4	3
208	Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. Lung Cancer, 2006, 51, 137-138.	0.9	3
209	Comment on â€˜Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesotheliomaâ€™. British Journal of Cancer, 2014, 111, 2376-2376.	2.9	3
210	Editorial: Emerging Therapies for Malignant Mesothelioma. Frontiers in Oncology, 2020, 10, 939.	1.3	3
211	Radioimmunotherapy of small-cell lung cancer xenografts using 131 I-labelled anti-NCAM monoclonal antibody 123C3. Cancer Immunology, Immunotherapy, 1995, 41, 169-174.	2.0	3
212	Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?. Annals of Cardiothoracic Surgery, 2012, 1, 481-6.	0.6	3
213	Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. European Journal of Cancer & Clinical Oncology, 1988, 24, 1529-1530.	0.9	2
214	Toxicity and supportive care in small cell lung cancer: a consensus report. Lung Cancer, 1989, 5, 146-151.	0.9	2
215	Development of cylindrical diffusing fibres suitable for interstitial photodynamic therapy. Lasers in Medical Science, 1993, 8, 93-98.	1.0	2
216	Chemoprevention of lung cancer: soon daily practice?. Expert Review of Anticancer Therapy, 2003, 3, 91-98.	1.1	2

#	Article	IF	Citations
217	clairvoyance or reliable prediction of the future?. Annals of Oncology, 2007, 18, 407-408.	0.6	2
218	Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study. International Journal of Occupational and Environmental Health, 2016, 22, 167-172.	1.2	2
219	OA02.01 The microRNA-15/16 Family Regulates Tumor Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S246.	0.5	2
220	OA22.06 Refinement of the Prognostic miR-Score for Use in Diagnostic Specimens from Chemo-NaÃ¯ve Malignant Pleural Mesothelioma Patients. Journal of Thoracic Oncology, 2017, 12, S332.	0.5	2
221	Patterns of care and survival of older patients with malignant pleural mesothelioma. Journal of Geriatric Oncology, 2019, 10, 573-576.	0.5	2
222	The COVID-19 outbreak: a snapshot from down under. Expert Review of Anticancer Therapy, 2020, 20, 433-436.	1.1	2
223	182. European chemoprevention trials in patients with lung cancer or head and neck cancer, using high dose retinol palmitate (RP) and N-acetyl-cysteine (NAC). Biomedicine and Pharmacotherapy, 1992, 46, 331.	2.5	1
224	MTE29.02 Advances in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S182-S184.	0.5	1
225	OA02.05 Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumor Microenvironment. Journal of Thoracic Oncology, 2017, 12, S248.	0.5	1
226	Asbestos and the Pathophysiology of Mesothelioma. , 2019, , 19-33.		1
227	Covalent binding of molecules to plasma immersion ion implantationâ€activated microparticles for delivery into cells. Engineering Reports, 2020, 2, e12087.	0.9	1
228	Individualization of treatment in non-small cell lung cancer. F1000 Medicine Reports, 2009, 1, .	2.9	1
229	Randomized phase I and pharmacological study of weekly or 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer. British Journal of Clinical Pharmacology, 2002, 54, 554-555.	1.1	0
230	M11-02: Chemoprevention 2007. Journal of Thoracic Oncology, 2007, 2, S183-S184.	0.5	0
231	1004 POSTER In vivo imaging of apoptosis by Annexin V scintigraphy: predictive value for treatment outcome. European Journal of Cancer, Supplement, 2007, 5, 136.	2.2	0
232	6575 POSTER Is there still a place for surgery in the treatment of locally-advanced non-small cell lung cancer (IIIA, N2)?. European Journal of Cancer, Supplement, 2007, 5, 380-381.	2.2	0
233	Reply to L.H. de Lima AraÃºjo et al. Journal of Clinical Oncology, 2010, 28, e26-e26.	0.8	0
234	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?. Chest, 2013, 144, 1971.	0.4	0

#	Article	IF	Citations
235	Using a multidisciplinary approach to combat the burden of asbestosâ€related disease. Medical Journal of Australia, 2016, 204, 52-52.	0.8	0
236	O32-5â€...The australian mesothelioma registry â€“ notifications, case characteristics and asbestos exposures. , 2016, , .		0
237	P3.03-007 miR-137 Acts as a Tumor Suppressor viaÂthe Down-Regulation of YB-1 in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1347-S1348.	0.5	0
238	ED13.02 Tissue-Based Biomarkers. Journal of Thoracic Oncology, 2017, 12, S57-S58.	0.5	0
239	P3.03-002 Inducible Changes in Cell Morphology and Gene Expression Reflecting the Histological Subtypes of Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1344.	0.5	0
240	P3.03-008 Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance inÂa 3D Model of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1348.	0.5	0
241	P3.03-033 The Influence of Geographic and Socioeconomic Factors on Prognosis andÂTreatment Provision in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1364-S1365.	0.5	0
242	OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study. Journal of Thoracic Oncology, 2017, 12, S247-S248.	0.5	0
243	Chemoprevention of Lung Cancer and Management of Early Lung Cancer. , 2018, , 69-81.e5.		0
244	D6-07: A seventy two gene signature and survival in completely-resected non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, S409.	0.5	0
245	Abstract LB-352: Functional significance of Zic1 and hsa-miR-23a over-expression in malignant mesothelioma. , 2011, , .		0
246	A novel microRNA-based treatment approach for malignant pleural mesothelioma.. Journal of Clinical Oncology, 2013, 31, 7586-7586.	0.8	0
247	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2014, 32, 7580-7580.	0.8	0
248	Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2014, 32, 7586-7586.	0.8	0
249	Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma.. Journal of Clinical Oncology, 2014, 32, e18543-e18543.	0.8	0
250	Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC. I Supplementi Di Tumori, 2002, 1, S37-8.	0.1	0